Loading...
Potent antiretroviral therapy (ART) was developed and validated against HIV-1 subtype B, and initially many experts worried that patients with non–subtype B infection (which predominates in the developing world) might respond differently to standard regimens than would those with subtype B. Data from observational studies have helped to assuage these fears, but there have been few, if any, direct comparisons of clinical response by subtype.
Researchers compiled treatment results on more than 2000 adults who began combination ART in the U.K. and had pretreatment genotyping information available for subgroup analysis. Overall, 73% of study participants had subtype B infection, 13% had subtype C, 3% each had subtypes A and CRF_AG, and 2% had su…